News


All News

The word of the moment is "new!" We have a new year, a new president, we are looking at the possibility of another new organizational structure in medicine, and we are working on a new look here at Dermatology Times.

Coding 2017 and beyond

Recent Medicare changes include the apparent disappearance of consultation codes, the addition of site-specific soft-tissue excision codes, and increasing pressure from overseers and auditors, says an expert.

Insurers tend to think of keloids as a cosmetic issue so they have a wide range of standards covering reimbursement for care and treatments. Practitioners must fully document the medical necessity of the care they provide and then code the conditions and treatments correctly to maximize their chance for reimbursement.

Cellfina is subscision of the fibrous attachments between the skin and fat layers. It is the only FDA-cleared device to have solid three-year data showing that the cellulite doesn’t come back, expert says.

Immune checkpoint inhibitors are providing rapid and durable responses for patients with metastatic Merkel cell carcinoma.

Diagnosing melanoma

Newer tools to help diagnose challenging lesions include combined immunohistochemical stains and a growing array of genetic tests, one of which has shown the potential to gauge metastatic risk.

A U.S. dermatologist shares his experience working with a Chinese plastic surgeon who does a high-volume of scar treatments.

Research in dermatology comprises only a small portion of the total amount of money spent yearly on research in fields such as internal medicine, neurology and cancer. The need for interested and talented individuals to tackle the big challenges in dermatology is greater than ever before, and practitioners are looking at ways to make the most of limitations in funding, compensation and opportunities that stand in the way of recruiting more qualified individuals to the research ranks.

Laser treatments, non-steroid injectables, and topical applications of imiquimod cream are proving to be effective in the treatment of keloids and excessive scarring. In many cases, recurrence rates have dropped to 20% and lower from former highs of 70% or more.

Rosacea treatments

Newer topical agents for rosacea including ivermectin and brimonidine are effective, and soon could be joined by oxymetazoline cream, experts say. Initial results from phase 2 trials of minocycline foam in rosacea could be available by year's end.

For decades, a lack of scientific data and evidence-based medicine have resulted in essentially no changes in the treatment of keloid disorder. New studies confirm that cryotherapy and intralesional injections of vincristine can be effective treatments for different types of keloids.

"While there is little that can be done from a medical perspective to improve the ridges, cosmetic improvement is possible," says Zoe Diana Draelos, M.D.

Melanoma’s burden is increasing and the rising rates cannot simply be attributed to increased disease detection, according to a research letter published last month in JAMA Dermatology.

In 2016, Dermatology Times provided several articles offering guidance on the business side of dermatology. Spanning such topics as using social media effectively, to designing the ideal office space and whether or not a cash-based model is right for you, these were the top five practice management articles of 2016.